---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-24-000106"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:19:32.710001+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zentalis Q1 cash $489M; multiple azenosertib data readouts H2 2024–2025

## Summary
- Cash, equivalents & marketable securities $489.0M (incl $56.7M Immunome stock); projected runway to mid-2026.
- R&D expense $49.6M (up $1M YoY); G&A $15.7M (down $0.7M). Quarterly net loss not disclosed.
- Key milestones: Phase 1 osteosarcoma data at 2024 ASCO; DENALI (PROC) topline H1 2025; TETON (USC) topline H2 2025.
- Interim CFO Cam Gallagher appointed April 5, 2024; search for permanent CFO underway.
- Azenosertib development on track with partnerships (GSK, Pfizer); registration-enabling trial in PSOC planned for 2025.

## SEC filing metadata
- accession: 0001725160-24-000106
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000106/0001725160-24-000106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000106/zntl-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-24-000106
- JSON: https://secwatch.observer/filing/0001725160-24-000106.json
- Plain text: https://secwatch.observer/filing/0001725160-24-000106.txt

## Key facts
- Earnings Releases
  Zentalis Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 7, 2024, Zentalis Pharmaceuticals, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2024 and commented on certain business updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000106/0001725160-24-000106-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.